{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:43:26Z","timestamp":1791549806715,"version":"4.3.4"},"reference-count":183,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10787-025-01983-9","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:34:38Z","timestamp":1758983678000},"page":"5945-5961","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Targeting the awry A\u03b2 pathway in Alzheimer\u2019s disease: hype and hurdles"],"prefix":"10.1007","volume":"33","author":[{"given":"Hayder M.","family":"Al-kuraishy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-3849","authenticated-orcid":false,"given":"Ghassan M.","family":"Sulaiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdoon A.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Albuhadily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosleh M.","family":"Abomughaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"1983_CR1","unstructured":"A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants with Early Alzheimer\u2019s Disease (MissionAD1)."},{"key":"1983_CR2","unstructured":"A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer\u2019s Disease."},{"key":"1983_CR3","doi-asserted-by":"crossref","unstructured":"Aanchal; Buttar, H.S.; Kaur, G.; Dziewiecka, H.; Skarpa\u0144ska-Stejnborn, A.; Walia, R. Chapter 56 - Multiple Therapeutic Applications of Bovine Colostrum and Its Bioactive Ingredients in Health and Disease with Special Reference to the Management of Neurodegenerative Disorders: A Comprehensive Review. In Molecular Medicine and Biomedical Research in the Era of Precision Medicine; Sobti, R.C., Wilson, D.W., Buttar, H.S., T\u00e9lessy, I.G., Sobti, A., Eds.; Academic Press, 2025; pp. 1223\u20131248 ISBN 978\u20130\u2013443\u201322300\u20136.","DOI":"10.1016\/B978-0-443-22300-6.00039-5"},{"key":"1983_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cpt.1570","volume":"107","author":"JE Ahn","year":"2020","unstructured":"Ahn JE, Carrieri C, Dela Cruz F, Fullerton T, Hajos-Korcsok E, He P, Kantaridis C, Leurent C, Liu R, Mancuso J et al (2020) Pharmacokinetic and Pharmacodynamic Effects of a \u03b3-Secretase Modulator, PF-06648671, on CSF Amyloid-\u03b2 Peptides in Randomized Phase I Studies. Clin Pharmacol Ther 107:211\u2013220. https:\/\/doi.org\/10.1002\/cpt.1570","journal-title":"Clin Pharmacol Ther"},{"key":"1983_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1017\/S1748232107000171","volume":"3","author":"PS Aisen","year":"2008","unstructured":"Aisen PS, Briand R, Laurin J, Duong A, Garceau D (2008) Targeting amyloid with Tramiprosate in patients with mild-to-moderate Alzheimer disease. Prog Neurother Neuropsychopharmacol 3:111\u2013125. https:\/\/doi.org\/10.1017\/S1748232107000171","journal-title":"Prog Neurother Neuropsychopharmacol"},{"key":"1983_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/aoms.2011.20612","volume":"7","author":"PS Aisen","year":"2011","unstructured":"Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC et al (2011) Tramiprosate in mild-to-moderate Alzheimer\u2019s disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci 7:102\u2013111. https:\/\/doi.org\/10.5114\/aoms.2011.20612","journal-title":"Arch Med Sci"},{"key":"1983_CR7","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1007\/s10571-023-01392-y","volume":"43","author":"FH AlAnazi","year":"2023","unstructured":"AlAnazi FH, Al-Kuraishy HM, Alexiou A, Papadakis M, Ashour MHM, Alnaaim SA, Elhussieny O, Saad HM, Batiha GE-S (2023) Primary hypothyroidism and Alzheimer\u2019s disease: a tale of two. Cell Mol Neurobiol 43:3405\u20133416. https:\/\/doi.org\/10.1007\/s10571-023-01392-y","journal-title":"Cell Mol Neurobiol"},{"key":"1983_CR8","volume":"45","author":"HM Al-kuraishy","year":"2025","unstructured":"Al-kuraishy HM, Sulaiman GM, Mohammed HA, Dawood RA, Albuhadily AK, Al-Gareeb AI, Abomughaid MM, Klionsky DJ (2025) Alterations in the processing of platelet APP (amyloid beta precursor protein) in Alzheimer disease: the possible nexus. Neuropsychopharmacol Rep 45:e12525","journal-title":"Neuropsychopharmacol Rep"},{"key":"1983_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-025-01796-w","author":"HM Al-Kuraishy","year":"2025","unstructured":"Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Saad HM, Al-Gareeb AI, Albuhadily AK (2025a) Targeting the JAK\/STAT3\/SOCS signaling pathway in Alzheimer\u2019s disease. Inflammopharmacology. https:\/\/doi.org\/10.1007\/s10787-025-01796-w","journal-title":"Inflammopharmacology"},{"key":"1983_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2025.115524","author":"HM Al-Kuraishy","year":"2025","unstructured":"Al-Kuraishy HM, Sulaiman GM, Mohammed HA, Al-Gareeb AI, Albuhadily AK, Mohammed SG (2025b) Role of RhoA-ROCK signaling inhibitor Fasudil in Alzheimer disease. Behav Brain Res. https:\/\/doi.org\/10.1016\/j.bbr.2025.115524","journal-title":"Behav Brain Res"},{"key":"1983_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-025-08857-x","volume":"27","author":"SM Alqahtani","year":"2025","unstructured":"Alqahtani SM, Al-Kuraishy HM, Al Gareeb AI, Albuhadily AK, Alexiou A, Papadakis M, Hemeda LR, Faheem SA, El-Saber Batiha G (2025) Unlocking Alzheimer\u2019s disease: the role of BDNF signaling in neuropathology and treatment. Neuromolecular Med 27:36. https:\/\/doi.org\/10.1007\/s12017-025-08857-x","journal-title":"Neuromolecular Med"},{"key":"1983_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70378","volume":"29","author":"MA Alsaleem","year":"2025","unstructured":"Alsaleem MA, Al-Kuraishy HM, Al-Gareeb AI, Abdel-Fattah MM, Alrouji M, Al-Harchan NA, Alruwaili M, Papadakis M, Alexiou A, Batiha GE-S (2025) Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer\u2019s Disease and Type 2 Diabetes: The Truth and Mystery. J Cell Mol Med 29:e70378. https:\/\/doi.org\/10.1111\/jcmm.70378","journal-title":"J Cell Mol Med"},{"key":"1983_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14656566.2024.2438317","volume":"26","author":"D Antony","year":"2025","unstructured":"Antony D, Sheth P, Swenson A, Smoller C, Maguire K, Grossberg G (2025) Recent advances in Alzheimer\u2019s disease therapy: clinical trials and literature review of novel enzyme inhibitors targeting amyloid precursor protein. Expert Opin Pharmacother 26:63\u201373. https:\/\/doi.org\/10.1080\/14656566.2024.2438317","journal-title":"Expert Opin Pharmacother"},{"key":"1983_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.88.16_supplement.P6.083","author":"V Asnaghi","year":"2017","unstructured":"Asnaghi V, Lin H, Rabbia M, Ostrowitzki S, Smith J, Cho W (2017) Long-term safety and tolerability of escalating doses of Crenezumab in patients with mild-to-moderate Alzheimer\u2019s disease (P6.083). Neurology. https:\/\/doi.org\/10.1212\/WNL.88.16_supplement.P6.083","journal-title":"Neurology"},{"key":"1983_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.expneurol.2013.10.001","volume":"250","author":"N Aytan","year":"2013","unstructured":"Aytan N, Choi J-K, Carreras I, Kowall NW, Jenkins BG, Dedeoglu A (2013) Combination therapy in a transgenic model of Alzheimer\u2019s disease. Exp Neurol 250:228\u2013238. https:\/\/doi.org\/10.1016\/j.expneurol.2013.10.001","journal-title":"Exp Neurol"},{"key":"1983_CR16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13041-024-01118-1","volume":"17","author":"A Azargoonjahromi","year":"2024","unstructured":"Azargoonjahromi A (2024) The duality of Amyloid-\u03b2: its role in normal and Alzheimer\u2019s disease states. Mol Brain 17:44. https:\/\/doi.org\/10.1186\/s13041-024-01118-1","journal-title":"Mol Brain"},{"key":"1983_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2013.06.004","author":"C Bachmeier","year":"2013","unstructured":"Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D (2013) Role of the cannabinoid system in the transit of Beta-amyloid across the blood-brain barrier. Mol Cell Neurosci. https:\/\/doi.org\/10.1016\/j.mcn.2013.06.004","journal-title":"Mol Cell Neurosci"},{"key":"1983_CR18","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1002\/fsn3.3187","volume":"11","author":"H Banasiak-Cie\u015blar","year":"2023","unstructured":"Banasiak-Cie\u015blar H, Wiener D, Kuszczyk M, Dobrzy\u0144ska K, Polanowski A (2023) Proline-rich polypeptides (Colostrinin(\u00ae)\/COLOCO(\u00ae)) modulate BDNF concentration in blood affecting cognitive function in adults: a double-blind randomized placebo-controlled study. Food Sci Nutr 11:1477\u20131485. https:\/\/doi.org\/10.1002\/fsn3.3187","journal-title":"Food Sci Nutr"},{"key":"1983_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1755-5949.2010.00231.x","volume":"18","author":"SR Bareggi","year":"2012","unstructured":"Bareggi SR, Cornelli U (2012) Clioquinol: review of its mechanisms of action and clinical uses in neurodegenerative disorders. CNS Neurosci Ther 18:41\u201346. https:\/\/doi.org\/10.1111\/j.1755-5949.2010.00231.x","journal-title":"CNS Neurosci Ther"},{"key":"1983_CR20","doi-asserted-by":"crossref","first-page":"10328","DOI":"10.1021\/bi201371j","volume":"50","author":"PJ Barrett","year":"2011","unstructured":"Barrett PJ, Sanders CR, Kaufman SA, Michelsen K, Jordan JB (2011) Nsaid-based \u03b3-secretase modulators do not bind to the amyloid-\u03b2 polypeptide. Biochemistry 50:10328\u201310342","journal-title":"Biochemistry"},{"key":"1983_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2020.101801","volume":"194","author":"G Barthet","year":"2020","unstructured":"Barthet G, Mulle C (2020) Presynaptic failure in Alzheimer\u2019s disease. Prog Neurobiol 194:101801. https:\/\/doi.org\/10.1016\/j.pneurobio.2020.101801","journal-title":"Prog Neurobiol"},{"key":"1983_CR22","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","volume":"64","author":"AJ Bayer","year":"2005","unstructured":"Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic A\u03b242 (AN1792) in patients with AD. Neurology 64:94\u2013101","journal-title":"Neurology"},{"key":"1983_CR23","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27248823","volume":"27","author":"FH Bazzari","year":"2022","unstructured":"Bazzari FH, Bazzari AH (2022) Bace1 inhibitors for Alzheimer\u2019s disease: the past, present and any future? Molecules 27:8823","journal-title":"Molecules"},{"key":"1983_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/bies.202200086","volume":"44","author":"A Bigi","year":"2022","unstructured":"Bigi A, Cascella R, Chiti F, Cecchi C (2022) Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseases. BioEssays 44:e2200086. https:\/\/doi.org\/10.1002\/bies.202200086","journal-title":"BioEssays"},{"key":"1983_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3233\/jad-2004-6103","volume":"6","author":"A Bilikiewicz","year":"2004","unstructured":"Bilikiewicz A, Gaus W (2004) Colostrinin (a Naturally Occurring, Proline-Rich, Polypeptide Mixture) in the Treatment of Alzheimer\u2019s Disease. J Alzheimers Dis 6:17\u201326. https:\/\/doi.org\/10.3233\/jad-2004-6103","journal-title":"J Alzheimers Dis"},{"key":"1983_CR26","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/mp.2015.74","volume":"20","author":"M Brendel","year":"2015","unstructured":"Brendel M, Jaworska A, Herms J, Trambauer J, R\u00f6tzer C, Gildehaus F-J, Carlsen J, Cumming P, Bylund J, Luebbers T et al (2015) Amyloid-PET predicts inhibition of de novo plaque formation upon chronic \u03b3-secretase modulator treatment. Mol Psychiatry 20:1179\u20131187. https:\/\/doi.org\/10.1038\/mp.2015.74","journal-title":"Mol Psychiatry"},{"key":"1983_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207452","author":"VN Bukke","year":"2020","unstructured":"Bukke VN, Archana M, Villani R, Romano AD, Wawrzyniak A, Balawender K, Orkisz S, Beggiato S, Serviddio G, Cassano T (2020) The dual role of glutamatergic neurotransmission in Alzheimer\u2019s disease: from pathophysiology to pharmacotherapy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21207452","journal-title":"Int J Mol Sci"},{"key":"1983_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2377-14-12","volume":"14","author":"AH Burstein","year":"2014","unstructured":"Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AMM (2014) Effect of TTP488 in patients with mild to moderate Alzheimer\u2019s disease. BMC Neurol 14:12. https:\/\/doi.org\/10.1186\/1471-2377-14-12","journal-title":"BMC Neurol"},{"key":"1983_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2018.18","volume":"5","author":"AH Burstein","year":"2018","unstructured":"Burstein AH, Sabbagh M, Andrews R, Valcarce C, Dunn I, Altstiel L (2018) Development of Azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer\u2019s disease. J Prev Alzheimers Dis 5:149\u2013154. https:\/\/doi.org\/10.14283\/jpad.2018.18","journal-title":"J Prev Alzheimers Dis"},{"key":"1983_CR30","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cpdd.689","volume":"8","author":"AH Burstein","year":"2019","unstructured":"Burstein AH, Brantley SJ, Dunn I, Altstiel LD, Schmith V (2019) Assessment of azeliragon QTc liability through integrated, model-based concentration QTc analysis. Clin Pharmacol Drug Dev 8:426\u2013435. https:\/\/doi.org\/10.1002\/cpdd.689","journal-title":"Clin Pharmacol Drug Dev"},{"key":"1983_CR31","doi-asserted-by":"crossref","unstructured":"Burstein, A.H.; Dunn, I.; Gooch, A.; Valcarce, C. Effects of Azeliragon on ADAS-Cog and CDR Domains and Individual Items in Patients with Mild Alzheimer\u2019s Disease and Type 2 Diabetes (T2D). Ethnicity 2020, 1, 0.","DOI":"10.1002\/alz.041198"},{"key":"1983_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12035-012-8251-3","volume":"45","author":"V Cavallucci","year":"2012","unstructured":"Cavallucci V, D\u2019Amelio M, Cecconi F (2012) A\u03b2 toxicity in Alzheimer\u2019s disease. Mol Neurobiol 45:366\u2013378. https:\/\/doi.org\/10.1007\/s12035-012-8251-3","journal-title":"Mol Neurobiol"},{"key":"1983_CR33","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.4049\/jimmunol.181.6.4272","volume":"181","author":"Y Chen","year":"2008","unstructured":"Chen Y, Akirav EM, Chen W, Henegariu O, Moser B, Desai D, Shen JM, Webster JC, Andrews RC, Mjalli AM et al (2008) RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol 181:4272\u20134278. https:\/\/doi.org\/10.4049\/jimmunol.181.6.4272","journal-title":"J Immunol"},{"key":"1983_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.104382","volume":"105","author":"T Chen","year":"2020","unstructured":"Chen T, Yang Y, Zhu S, Lu Y, Zhu L, Wang Y, Wang X (2020) Inhibition of A\u03b2 aggregates in Alzheimer\u2019s disease by Epigallocatechin and Epicatechin-3-gallate from green tea. Bioorg Chem 105:104382. https:\/\/doi.org\/10.1016\/j.bioorg.2020.104382","journal-title":"Bioorg Chem"},{"key":"1983_CR35","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1021\/acschemneuro.1c00306","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li X, Zhan C, Lao Z, Li F, Dong X, Wei G (2021) A comprehensive insight into the mechanisms of dopamine in disrupting A\u03b2 protofibrils and inhibiting A\u03b2 aggregation. ACS Chem Neurosci 12:4007\u20134019. https:\/\/doi.org\/10.1021\/acschemneuro.1c00306","journal-title":"ACS Chem Neurosci"},{"key":"1983_CR36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13041-022-00948-1","volume":"15","author":"H-J Choi","year":"2022","unstructured":"Choi H-J, Park J-H, Jeong YJ, Hwang J-W, Lee S, Lee H, Seol E, Kim I-W, Cha B-Y, Seo J et al (2022) Donepezil ameliorates A\u03b2 pathology but not tau pathology in 5xFAD mice. Mol Brain 15:63. https:\/\/doi.org\/10.1186\/s13041-022-00948-1","journal-title":"Mol Brain"},{"key":"1983_CR37","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cpt.1258","volume":"105","author":"K Chris Min","year":"2019","unstructured":"Chris Min K, Dockendorf MF, Palcza J, Tseng J, Ma L, Stone JA, Kleijn HJ, Hodsman P, Masuo K, Tanen M et al (2019) Pharmacokinetics and Pharmacodynamics of the BACE1 Inhibitor Verubecestat (MK-8931) in Healthy Japanese Adults: A Randomized. Placebo-Controlled Study Clin Pharmacol Ther 105:1234\u20131243. https:\/\/doi.org\/10.1002\/cpt.1258","journal-title":"Placebo-Controlled Study Clin Pharmacol Ther"},{"issue":"s1","key":"1983_CR38","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.3233\/JAD-240146","volume":"101","author":"JRM Coimbra","year":"2024","unstructured":"Coimbra JRM, Resende R, Cust\u00f3dio JBA, Salvador JAR, Santos AE (2024) BACE1 inhibitors for Alzheimer\u2019s disease: current challenges and future perspectives. J Alzheimers Dis 101(s1):S53\u2013S78. https:\/\/doi.org\/10.3233\/JAD-240146","journal-title":"J Alzheimers Dis"},{"key":"1983_CR39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14:399\u2013415","journal-title":"Nat Rev Neurol"},{"key":"1983_CR40","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","volume":"69","author":"V Coric","year":"2012","unstructured":"Coric V, Van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G (2012) Safety and tolerability of the \u03b3-secretase inhibitor Avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 69:1430\u20131440","journal-title":"Arch Neurol"},{"key":"1983_CR41","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1021\/bi400377p","volume":"52","author":"CJ Crump","year":"2013","unstructured":"Crump CJ, Johnson DS, Li Y-M (2013) Development and mechanism of \u03b3-secretase modulators for Alzheimer\u2019s disease. Biochemistry 52:3197\u20133216","journal-title":"Biochemistry"},{"key":"1983_CR42","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1002\/med.22033","volume":"44","author":"V Das","year":"2024","unstructured":"Das V, Miller JH, Alladi CG, Annadurai N, De Sanctis JB, Hrub\u00e1 L, Hajd\u00fach M (2024) Antineoplastics for treating Alzheimer\u2019s disease and dementia: evidence from preclinical and observational studies. Med Res Rev 44:2078\u20132111. https:\/\/doi.org\/10.1002\/med.22033","journal-title":"Med Res Rev"},{"key":"1983_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1208\/s12248-014-9605-8","volume":"16","author":"Y Deng","year":"2014","unstructured":"Deng Y, Lu X, Wang L, Li T, Ding Y, Cao H, Zhang Y, Guo X, Yu G (2014) Curcumin inhibits the AKT\/NF-\u039aB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line. AAPS J 16:649\u2013657. https:\/\/doi.org\/10.1208\/s12248-014-9605-8","journal-title":"AAPS J"},{"key":"1983_CR44","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1017\/S1461145713000631","volume":"16","author":"M Dobarro","year":"2013","unstructured":"Dobarro M, Gerenu G, Ram\u00edrez MJ (2013) Propranolol reduces cognitive deficits, amyloid and tau pathology in Alzheimer\u2019s transgenic mice. Int J Neuropsychopharmacol 16:2245\u20132257. https:\/\/doi.org\/10.1017\/S1461145713000631","journal-title":"Int J Neuropsychopharmacol"},{"key":"1983_CR45","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","volume":"369","author":"RS Doody","year":"2013","unstructured":"Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG (2013) A phase 3 trial of Semagacestat for treatment of Alzheimer\u2019s disease. N Engl J Med 369:341\u2013350","journal-title":"N Engl J Med"},{"key":"1983_CR46","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370:311\u2013321. https:\/\/doi.org\/10.1056\/NEJMoa1312889","journal-title":"N Engl J Med"},{"key":"1983_CR47","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fnagi.2019.00182","volume":"11","author":"M Dos Santos Guilherme","year":"2019","unstructured":"Dos Santos Guilherme M, Stoye NM, Rose-John S, Garbers C, Fellgiebel A, Endres K (2019) The synthetic retinoid acitretin increases IL-6 in the central nervous system of Alzheimer disease model mice and human patients. Front Aging Neurosci 11:182. https:\/\/doi.org\/10.3389\/fnagi.2019.00182","journal-title":"Front Aging Neurosci"},{"key":"1983_CR48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1471-4159.2001.00012.x","volume":"76","author":"HF Dovey","year":"2001","unstructured":"Dovey HF, John V, Anderson JP, Chen LZ, de Saint Andrieu P, Fang LY, Freedman SB, Folmer B, Goldbach E, Holsztynska EJ (2001) Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76:173\u2013181","journal-title":"J Neurochem"},{"key":"1983_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neuint.2013.02.006","volume":"62","author":"M Ejaz Ahmed","year":"2013","unstructured":"Ejaz Ahmed M, Khan MM, Javed H, Vaibhav K, Khan A, Tabassum R, Ashafaq M, Islam F, Safhi MM, Islam F (2013) Amelioration of cognitive impairment and neurodegeneration by catechin hydrate in rat model of streptozotocin-induced experimental dementia of Alzheimer\u2019s type. Neurochem Int 62:492\u2013501. https:\/\/doi.org\/10.1016\/j.neuint.2013.02.006","journal-title":"Neurochem Int"},{"key":"1983_CR50","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","volume":"83","author":"K Endres","year":"2014","unstructured":"Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, T\u00fcscher O, Fellgiebel A (2014) Increased CSF APPs-\u03b1 levels in patients with Alzheimer disease treated with acitretin. Neurology 83:1930\u20131935. https:\/\/doi.org\/10.1212\/WNL.0000000000001017","journal-title":"Neurology"},{"key":"1983_CR51","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1016\/j.neuron.2023.07.005","volume":"111","author":"S Essayan-Perez","year":"2023","unstructured":"Essayan-Perez S, S\u00fcdhof TC (2023) Neuronal \u03b3-secretase regulates lipid metabolism, linking cholesterol to synaptic dysfunction in Alzheimer\u2019s disease. Neuron 111:3176\u20133194","journal-title":"Neuron"},{"key":"1983_CR52","doi-asserted-by":"publisher","unstructured":"Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019. Lancet. Public Heal. 2022, 7, e105\u2013e125, https:\/\/doi.org\/10.1016\/S2468-2667(21)00249-8.","DOI":"10.1016\/S2468-2667(21)00249-8"},{"key":"1983_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12264-019-00429-x","volume":"36","author":"D-Y Fan","year":"2020","unstructured":"Fan D-Y, Wang Y-J (2020) Early intervention in Alzheimer\u2019s disease: how early is early enough? Neurosci Bull 36:195\u2013197. https:\/\/doi.org\/10.1007\/s12264-019-00429-x","journal-title":"Neurosci Bull"},{"key":"1983_CR54","unstructured":"Friedemann P. Sunphenon EGCg (Epigallocatechin-Gallate) in the Early Stage of Alzheimer\u2019s Disease."},{"key":"1983_CR55","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.170228","author":"GR Frost","year":"2017","unstructured":"Frost GR, Li Y-M (2017) The role of astrocytes in amyloid production and Alzheimer\u2019s disease. Open Biol. https:\/\/doi.org\/10.1098\/rsob.170228","journal-title":"Open Biol"},{"key":"1983_CR56","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neuroscience.2020.07.020","volume":"443","author":"H Fu","year":"2020","unstructured":"Fu H, Liu B, Li L, Lemere CA (2020) Microglia do not take up soluble amyloid-beta peptides, but partially degrade them by secreting insulin-degrading enzyme. Neuroscience 443:30\u201343. https:\/\/doi.org\/10.1016\/j.neuroscience.2020.07.020","journal-title":"Neuroscience"},{"key":"1983_CR57","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1386207326666230419095813","volume":"27","author":"Y Gao","year":"2024","unstructured":"Gao Y, Guo J, Zhang F, Li Y (2024) Safety analysis of bapineuzumab in the treatment of mild to moderate Alzheimer\u2019s disease: a systematic review and meta-analysis. Comb Chem High Throughput Screen 27:40\u201347. https:\/\/doi.org\/10.2174\/1386207326666230419095813","journal-title":"Comb Chem High Throughput Screen"},{"key":"1983_CR58","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","volume":"13","author":"S Gauthier","year":"2009","unstructured":"Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W et al (2009) Effect of tramiprosate in patients with mild-to-moderate Alzheimer\u2019s disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging 13:550\u2013557. https:\/\/doi.org\/10.1007\/s12603-009-0106-x","journal-title":"J Nutr Health Aging"},{"key":"1983_CR59","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/clc.22678","volume":"40","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS et al (2017a) Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-a cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol 40:59\u201365. https:\/\/doi.org\/10.1002\/clc.22678","journal-title":"Clin Cardiol"},{"key":"1983_CR60","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Sabatine MS, Ott BR (2017b) Cognitive function in a randomized trial of Evolocumab. N Engl J Med 377:1997","journal-title":"N Engl J Med"},{"key":"1983_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.937133","volume":"15","author":"P Goel","year":"2022","unstructured":"Goel P, Chakrabarti S, Goel K, Bhutani K, Chopra T, Bali S (2022) Neuronal cell death mechanisms in Alzheimer\u2019s disease: an insight. Front Mol Neurosci 15:937133. https:\/\/doi.org\/10.3389\/fnmol.2022.937133","journal-title":"Front Mol Neurosci"},{"key":"1983_CR62","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1017\/S0007114515004687","volume":"115","author":"KG Goozee","year":"2016","unstructured":"Goozee KG, Shah TM, Sohrabi HR, Rainey-Smith SR, Brown B, Verdile G, Martins RN (2016) Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer\u2019s disease. Br J Nutr 115:449\u2013465. https:\/\/doi.org\/10.1017\/S0007114515004687","journal-title":"Br J Nutr"},{"key":"1983_CR63","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","volume":"302","author":"R Green","year":"2009","unstructured":"Green R, Schneider L, Amato D, Beelen A, Wilcock G, Swabb E, Zavitz K (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302:2557\u20132564. https:\/\/doi.org\/10.1001\/jama.2009.1866","journal-title":"JAMA"},{"key":"1983_CR64","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/nbm.1132","volume":"20","author":"HR Griffith","year":"2007","unstructured":"Griffith HR, den Hollander JA, Stewart CC, Evanochko WT, Buchthal SD, Harrell LE, Zamrini EY, Brockington JC, Marson DC (2007) Elevated brain scyllo\u2010inositol concentrations in patients with Alzheimer\u2019s disease. NMR Biomed 20:709\u2013716. https:\/\/doi.org\/10.1002\/nbm.1132","journal-title":"NMR Biomed"},{"key":"1983_CR65","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JAD-2009-1063","volume":"17","author":"C Grossi","year":"2009","unstructured":"Grossi C, Francese S, Casini A, Rosi MC, Luccarini I, Fiorentini A, Gabbiani C, Messori L, Moneti G, Casamenti F (2009) Clioquinol Decreases Amyloid-Beta Burden and Reduces Working Memory Impairment in a Transgenic Mouse Model of Alzheimer\u2019s Disease. J Alzheimers Dis 17:423\u2013440. https:\/\/doi.org\/10.3233\/JAD-2009-1063","journal-title":"J Alzheimers Dis"},{"key":"1983_CR66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semcdb.2020.05.019","volume":"105","author":"G G\u00fcner","year":"2020","unstructured":"G\u00fcner G, Lichtenthaler SF, Elsevier (2020) The substrate repertoire of \u03b3-secretase\/presenilin. Semin Cell Dev Biol 105:27\u201342 (Proceedings of the)","journal-title":"Semin Cell Dev Biol"},{"key":"1983_CR67","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.neuroscience.2015.01.058","volume":"290","author":"HB Guo","year":"2015","unstructured":"Guo HB, Cheng YF, Wu JG, Wang CM, Wang HT, Zhang C, Qiu ZK, Xu JP (2015) Donepezil improves learning and memory deficits in APP\/PS1 mice by inhibition of microglial activation. Neuroscience 290:530\u2013542. https:\/\/doi.org\/10.1016\/j.neuroscience.2015.01.058","journal-title":"Neuroscience"},{"key":"1983_CR68","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam M-M, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 141:1917\u20131933. https:\/\/doi.org\/10.1093\/brain\/awy132","journal-title":"Brain"},{"key":"1983_CR69","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.0000221429.94591.72","volume":"47","author":"Y Hattori","year":"2006","unstructured":"Hattori Y, Suzuki K, Hattori S, Kasai K (2006) Metformin inhibits cytokine-induced nuclear factor \u03bab activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 47:1183\u20131188","journal-title":"Hypertension"},{"key":"1983_CR70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature09325","volume":"467","author":"G He","year":"2010","unstructured":"He G, Luo W, Li P, Remmers C, Netzer WJ, Hendrick J, Bettayeb K, Flajolet M, Gorelick F, Wennogle LP et al (2010) Gamma-secretase activating protein is a therapeutic target for Alzheimer\u2019s disease. Nature 467:95\u201398. https:\/\/doi.org\/10.1038\/nature09325","journal-title":"Nature"},{"key":"1983_CR71","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000334300","volume":"10","author":"D Holthoewer","year":"2012","unstructured":"Holthoewer D, Endres K, Schuck F, Hiemke C, Schmitt U, Fahrenholz F (2012) Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein. Neurodegener Dis 10:224\u2013228. https:\/\/doi.org\/10.1159\/000334300","journal-title":"Neurodegener Dis"},{"key":"1983_CR72","doi-asserted-by":"crossref","unstructured":"Hone, E.; Lim, F.; Martins, I.J. Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer\u2019s Disease. Neurodegener. Alzheimer\u2019s Dis. Role Diabetes, Genet. Horm. Lifestyle 2019, 189\u2013231.","DOI":"10.1002\/9781119356752.ch7"},{"key":"1983_CR73","first-page":"827","volume":"17","author":"Q Hu","year":"2018","unstructured":"Hu Q, Yu B, Chen Q, Wang Y, Ling Y, Sun S, Shi Y, Zhou C (2018) Effect of linguizhugan decoction on neuroinflammation and expression disorder of the amyloid \u03b2-related transporters RAGE and LRP-1 in a rat model of Alzheimer\u2019s disease. Mol Med Rep 17:827\u2013834","journal-title":"Mol Med Rep"},{"key":"1983_CR74","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s12276-022-00754-8","volume":"54","author":"J-Y Hur","year":"2022","unstructured":"Hur J-Y (2022) \u03b3-secretase in Alzheimer\u2019s disease. Exp Mol Med 54:433\u2013446","journal-title":"Exp Mol Med"},{"key":"1983_CR75","doi-asserted-by":"publisher","first-page":"4032","DOI":"10.3390\/nu6104032","volume":"6","author":"K Ide","year":"2014","unstructured":"Ide K, Yamada H, Takuma N, Park M, Wakamiya N, Nakase J, Ukawa Y, Sagesaka YM (2014) Green tea consumption affects cognitive dysfunction in the elderly: a pilot study. Nutrients 6:4032\u20134042. https:\/\/doi.org\/10.3390\/nu6104032","journal-title":"Nutrients"},{"key":"1983_CR76","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/WAD.0b013e3182622ace","volume":"27","author":"BP Imbimbo","year":"2013","unstructured":"Imbimbo BP, Frigerio E, Breda M, Fiorentini F, Fernandez M, Sivilia S, Giardino L, Calza L, Norris D, Casula D (2013) Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects. Alzheimer Dis Assoc Disord 27:278\u2013286","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1983_CR77","doi-asserted-by":"publisher","first-page":"8573","DOI":"10.1007\/s12035-019-01678-7","volume":"56","author":"Y Inoue","year":"2019","unstructured":"Inoue Y, Ueda M, Masuda T, Misumi Y, Yamashita T, Ando Y (2019) Memantine, a noncompetitive N-methyl-D-aspartate receptor antagonist, attenuates cerebral amyloid angiopathy by increasing insulin-degrading enzyme expression. Mol Neurobiol 56:8573\u20138588. https:\/\/doi.org\/10.1007\/s12035-019-01678-7","journal-title":"Mol Neurobiol"},{"key":"1983_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2021.136136","volume":"762","author":"Y Inoue","year":"2021","unstructured":"Inoue Y, Masuda T, Misumi Y, Ando Y, Ueda M (2021) Metformin attenuates vascular pathology by increasing expression of insulin-degrading enzyme in a mixed model of cerebral amyloid angiopathy and type 2 diabetes mellitus. Neurosci Lett 762:136136. https:\/\/doi.org\/10.1016\/j.neulet.2021.136136","journal-title":"Neurosci Lett"},{"key":"1983_CR79","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0032-1321878","volume":"44","author":"Y Ishibashi","year":"2012","unstructured":"Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S (2012) Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Horm Metab Res 44:891\u2013895","journal-title":"Horm Metab Res"},{"key":"1983_CR80","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.diabres.2016.12.010","volume":"123","author":"AT Isik","year":"2017","unstructured":"Isik AT, Soysal P, Yay A, Usarel C (2017) The effects of Sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer\u2019s disease. Diabetes Res Clin Pract 123:192\u2013198","journal-title":"Diabetes Res Clin Pract"},{"key":"1983_CR81","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213483","volume":"104","author":"SY Jeong","year":"2025","unstructured":"Jeong SY, Suh CH, Lim J-S, Shim WH, Heo H, Choi Y, Kim HS, Kim SJ, Lee J-H (2025) Incidence of amyloid-related imaging abnormalities in phase III clinical trials of anti-amyloid-\u03b2 immunotherapy: an updated meta-analysis. Neurology 104:e213483. https:\/\/doi.org\/10.1212\/WNL.0000000000213483","journal-title":"Neurology"},{"key":"1983_CR82","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2020.586731","volume":"13","author":"S Jiang","year":"2020","unstructured":"Jiang S, Bhaskar K (2020) Degradation and transmission of Tau by autophagic-endolysosomal networks and potential therapeutic targets for tauopathy. Front Mol Neurosci 13:586731. https:\/\/doi.org\/10.3389\/fnmol.2020.586731","journal-title":"Front Mol Neurosci"},{"key":"1983_CR83","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40265-024-02087-4","volume":"84","author":"C Kang","year":"2024","unstructured":"Kang C (2024) Donanemab: first approval. Drugs 84:1313\u20131318. https:\/\/doi.org\/10.1007\/s40265-024-02087-4","journal-title":"Drugs"},{"key":"1983_CR84","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad9704","volume":"8","author":"ME Kennedy","year":"2016","unstructured":"Kennedy ME, Stamford AW, Chen X, Cox K, Cumming JN, Dockendorf MF, Egan M, Ereshefsky L, Hodgson RA, Hyde LA et al (2016) The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer\u2019s disease patients. Sci Transl Med 8:363ra150. https:\/\/doi.org\/10.1126\/scitranslmed.aad9704","journal-title":"Sci Transl Med"},{"key":"1983_CR85","first-page":"192","volume":"3","author":"N Ketter","year":"2016","unstructured":"Ketter N, Liu E, Di J, Honig LS, Lu M, Novak G, Werth J, LePrince Leterme G, Shadman A, Brashear HRA (2016) Randomized, Double-Blind, Phase 2 Study of the Effects of the Vaccine Vanutide Cridificar with QS-21 Adjuvant on Immunogenicity, Safety and Amyloid Imaging in Patients with Mild to Moderate Alzheimer\u2019s Disease. J Prev Alzheimer\u2019s Dis 3:192\u2013201","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"1983_CR86","doi-asserted-by":"publisher","first-page":"6454","DOI":"10.1038\/s41598-020-63550-2","volume":"10","author":"M Kim","year":"2020","unstructured":"Kim M, Park HE, Lee S-H, Han K, Lee JH (2020) Increased risk of Alzheimer\u2019s disease in patients with psoriasis: a nationwide population-based cohort study. Sci Rep 10:6454. https:\/\/doi.org\/10.1038\/s41598-020-63550-2","journal-title":"Sci Rep"},{"key":"1983_CR87","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ajcn\/83.2.355","volume":"83","author":"S Kuriyama","year":"2006","unstructured":"Kuriyama S, Hozawa A, Ohmori K, Shimazu T, Matsui T, Ebihara S, Awata S, Nagatomi R, Arai H, Tsuji I (2006) Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am J Clin Nutr 83:355\u2013361. https:\/\/doi.org\/10.1093\/ajcn\/83.2.355","journal-title":"Am J Clin Nutr"},{"key":"1983_CR88","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.tips.2017.10.008","volume":"39","author":"IV Kurochkin","year":"2018","unstructured":"Kurochkin IV, Guarnera E, Berezovsky IN (2018) Insulin-degrading enzyme in the fight against Alzheimer\u2019s disease. Trends Pharmacol Sci 39:49\u201358. https:\/\/doi.org\/10.1016\/j.tips.2017.10.008","journal-title":"Trends Pharmacol Sci"},{"key":"1983_CR89","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.102.048280","volume":"305","author":"TA Lanz","year":"2003","unstructured":"Lanz TA, Himes CS, Pallante G, Adams L, Yamazaki S, Amore B, Merchant KM (2003) The \u03b3-secretase inhibitor N-[N-(3, 5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A\u03b2 levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 305:864\u2013871","journal-title":"J Pharmacol Exp Ther"},{"key":"1983_CR90","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/jpet.106.110700","volume":"319","author":"TA Lanz","year":"2006","unstructured":"Lanz TA, Karmilowicz MJ, Wood KM, Pozdnyakov N, Du P, Piotrowski MA, Brown TM, Nolan CE, Richter KEG, Finley JE (2006) Concentration-dependent modulation of amyloid-\u03b2 in vivo and in vitro using the \u03b3-secretase inhibitor, LY-450139. J Pharmacol Exp Ther 319:924\u2013933","journal-title":"J Pharmacol Exp Ther"},{"key":"1983_CR91","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1471-4159.2011.07560.x","volume":"121","author":"T Li","year":"2011","unstructured":"Li T, Huang Y, Jin S, Ye L, Rong N, Yang X, Ding Y, Cheng Z, Zhang J, Wan Z et al (2011) \u03b3-Secretase Modulators Do Not Induce A\u03b2-Rebound and Accumulation of \u03b2-C-Terminal Fragment. J Neurochem 121:277\u2013286. https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07560.x","journal-title":"J Neurochem"},{"key":"1983_CR92","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1002\/chem.201905621","volume":"26","author":"G Li","year":"2020","unstructured":"Li G, Yang W-Y, Li W-H, Luo Y-Y, Lim Y-J, Li Y, Paul A, Segal D, Hong L, Li Y-M (2020) Rational design of a cocktail of inhibitors against A\u03b2 aggregation. Chemistry 26:3499\u20133503. https:\/\/doi.org\/10.1002\/chem.201905621","journal-title":"Chemistry"},{"key":"1983_CR93","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/j.1471-4159.2010.07081.x","volume":"116","author":"SF Lichtenthaler","year":"2011","unstructured":"Lichtenthaler SF (2011) Alpha-secretase in Alzheimer\u2019s disease: molecular identity, regulation and therapeutic potential. J Neurochem 116:10\u201321. https:\/\/doi.org\/10.1111\/j.1471-4159.2010.07081.x","journal-title":"J Neurochem"},{"key":"1983_CR94","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jnutbio.2012.10.005","volume":"24","author":"HJ Lim","year":"2013","unstructured":"Lim HJ, Shim SB, Jee SW, Lee SH, Lim CJ, Hong JT, Sheen YY, Hwang DY (2013) Green tea catechin leads to global improvement among Alzheimer\u2019s disease-related phenotypes in NSE\/HAPP-C105 Tg mice. J Nutr Biochem 24:1302\u20131313. https:\/\/doi.org\/10.1016\/j.jnutbio.2012.10.005","journal-title":"J Nutr Biochem"},{"key":"1983_CR95","doi-asserted-by":"crossref","first-page":"17851","DOI":"10.1038\/s41598-021-97361-w","volume":"11","author":"C-P Lin","year":"2021","unstructured":"Lin C-P, Huang P-H, Chen C-Y, Wu M-Y, Chen J-S, Chen J-W, Lin S-J (2021) Sitagliptin attenuates arterial calcification by downregulating oxidative stress-induced receptor for advanced glycation end products in LDLR knockout mice. Sci Rep 11:17851","journal-title":"Sci Rep"},{"key":"1983_CR96","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1111\/jnc.15762","volume":"164","author":"DA Loeffler","year":"2023","unstructured":"Loeffler DA (2023) Experimental approaches for altering the expression of Abeta\u2010degrading enzymes. J Neurochem 164:725\u2013763. https:\/\/doi.org\/10.1111\/jnc.15762","journal-title":"J Neurochem"},{"key":"1983_CR97","doi-asserted-by":"publisher","first-page":"2315106","DOI":"10.1155\/2020\/2315106","volume":"2020","author":"X-Y Lu","year":"2020","unstructured":"Lu X-Y, Huang S, Chen Q-B, Zhang D, Li W, Ao R, Leung FC-Y, Zhang Z, Huang J, Tang Y et al (2020) Metformin Ameliorates A\u03b2 Pathology by Insulin-Degrading Enzyme in a Transgenic Mouse Model of Alzheimer\u2019s Disease. Oxid Med Cell Longev 2020:2315106. https:\/\/doi.org\/10.1155\/2020\/2315106","journal-title":"Oxid Med Cell Longev"},{"key":"1983_CR98","doi-asserted-by":"publisher","first-page":"772","DOI":"10.2174\/1567205018666211208141017","volume":"18","author":"L Luu","year":"2021","unstructured":"Luu L, Ciccotosto GD, Cappai R (2021) The Alzheimer\u2019s disease amyloid precursor protein and its neuritogenic actions. Curr Alzheimer Res 18:772\u2013786. https:\/\/doi.org\/10.2174\/1567205018666211208141017","journal-title":"Curr Alzheimer Res"},{"key":"1983_CR99","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/B978-0-12-394816-8.00006-4","volume":"64","author":"K Ma","year":"2012","unstructured":"Ma K, Thomason LAM, McLaurin J (2012) Scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer\u2019s Disease. Adv Pharmacol 64:177\u2013212. https:\/\/doi.org\/10.1016\/B978-0-12-394816-8.00006-4","journal-title":"Adv Pharmacol"},{"key":"1983_CR100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115237","volume":"10","author":"M Mandler","year":"2015","unstructured":"Mandler M, Santic R, Gruber P, Cinar Y, Pichler D, Funke SA, Willbold D, Schneeberger A, Schmidt W, Mattner F (2015) Tailoring the antibody response to aggregated A\u00df using novel Alzheimer-vaccines. PLoS ONE 10:e0115237","journal-title":"PLoS ONE"},{"key":"1983_CR101","doi-asserted-by":"publisher","first-page":"4013","DOI":"10.1073\/pnas.1402228111","volume":"111","author":"KES Matlack","year":"2014","unstructured":"Matlack KES, Tardiff DF, Narayan P, Hamamichi S, Caldwell KA, Caldwell GA, Lindquist S (2014) Clioquinol promotes the degradation of metal-dependent amyloid-\u03b2 (A\u03b2) oligomers to restore endocytosis and ameliorate A\u03b2 toxicity. Proc Natl Acad Sci U S A 111:4013\u20134018. https:\/\/doi.org\/10.1073\/pnas.1402228111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1983_CR102","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/labinvest.2015.35","volume":"95","author":"T Matsui","year":"2015","unstructured":"Matsui T, Nakashima S, Nishino Y, Ojima A, Nakamura N, Arima K, Fukami K, Okuda S, Yamagishi S (2015) Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Lab Invest 95:525\u2013533","journal-title":"Lab Invest"},{"key":"1983_CR103","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04237-x","volume":"79","author":"AD Mazura","year":"2022","unstructured":"Mazura AD, Ohler A, Storck SE, Kurtyka M, Scharfenberg F, Weggen S, Becker-Pauly C, Pietrzik CU (2022) PCSK9 acts as a key regulator of A\u03b2 clearance across the blood-brain barrier. Cell Mol Life Sci 79:212. https:\/\/doi.org\/10.1007\/s00018-022-04237-x","journal-title":"Cell Mol Life Sci"},{"key":"1983_CR104","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/NRR.NRR-D-23-01781","volume":"20","author":"Y Miao","year":"2025","unstructured":"Miao Y, Wolfe MS (2025) Emerging structures and dynamic mechanisms of \u03b3-secretase for Alzheimer\u2019s disease. Neural Regen Res 20:174\u2013180","journal-title":"Neural Regen Res"},{"key":"1983_CR105","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1523\/JNEUROSCI.4264-11.2012","volume":"32","author":"Y Mitani","year":"2012","unstructured":"Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, Matsuoka N (2012) Differential effects between \u03b3-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice. J Neurosci 32:2037\u20132050","journal-title":"J Neurosci"},{"key":"1983_CR106","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116802","volume":"10","author":"J-A Mo","year":"2015","unstructured":"Mo J-A, Lim J-H, Sul A-R, Lee M, Youn YC, Kim H-J (2015) Cerebrospinal fluid \u03b2-amyloid1-42 levels in the differential diagnosis of Alzheimer\u2019s disease-systematic review and meta-analysis. PLoS ONE 10:e0116802. https:\/\/doi.org\/10.1371\/journal.pone.0116802","journal-title":"PLoS ONE"},{"key":"1983_CR107","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-021-00073-z","volume":"1","author":"A Montagne","year":"2021","unstructured":"Montagne A, Nikolakopoulou AM, Huuskonen MT, Sagare AP, Lawson EJ, Lazic D, Rege SV, Grond A, Zuniga E, Barnes SR et al (2021) APOE4 accelerates advanced-stage vascular and neurodegenerative disorder in old Alzheimer\u2019s mice via cyclophilin A independently of amyloid-\u03b2. Nat Aging 1:506\u2013520. https:\/\/doi.org\/10.1038\/s43587-021-00073-z","journal-title":"Nat Aging"},{"key":"1983_CR108","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3233\/JAD-2009-1230","volume":"19","author":"JE Morley","year":"2010","unstructured":"Morley JE, Farr SA, Banks WA, Johnson SN, Yamada KA, Xu L (2010) A Physiological Role for Amyloid-Beta Protein:Enhancement of Learning and Memory. J Alzheimers Dis 19:441\u2013449. https:\/\/doi.org\/10.3233\/JAD-2009-1230","journal-title":"J Alzheimers Dis"},{"key":"1983_CR109","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1080\/13543784.2017.1369527","volume":"26","author":"CE-H Moussa","year":"2017","unstructured":"Moussa CE-H (2017) Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer\u2019s disease. Expert Opin Investig Drugs 26:1131\u20131136. https:\/\/doi.org\/10.1080\/13543784.2017.1369527","journal-title":"Expert Opin Investig Drugs"},{"key":"1983_CR110","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1111\/bph.14593","volume":"176","author":"NN Nalivaeva","year":"2019","unstructured":"Nalivaeva NN, Turner AJ (2019) Targeting amyloid clearance in Alzheimer\u2019s disease as a therapeutic strategy. Br J Pharmacol 176:3447\u20133463. https:\/\/doi.org\/10.1111\/bph.14593","journal-title":"Br J Pharmacol"},{"key":"1983_CR111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2023.101888","volume":"32","author":"A Nayak","year":"2024","unstructured":"Nayak A, Raju R, Das P, Das K, Suvitha A, Meher BR, Alobid S, Almoteer AI, Almadani ME, Alshehri A (2024) Novel ibuprofen prodrug: a possible promising agent for the management of complications of Alzheimer\u2019s disease. Saudi Pharm J 32:101888","journal-title":"Saudi Pharm J"},{"key":"1983_CR112","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3233\/JAD-170161","volume":"58","author":"TJ Nelson","year":"2017","unstructured":"Nelson TJ, Sun M-K, Lim C, Sen A, Khan T, Chirila FV, Alkon DL (2017) Bryostatin effects on cognitive function and PKC\u025b in Alzheimer\u2019s disease phase IIa and expanded access trials. J Alzheimers Dis 58:521\u2013535. https:\/\/doi.org\/10.3233\/JAD-170161","journal-title":"J Alzheimers Dis"},{"key":"1983_CR113","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809316","volume":"10","author":"U Neumann","year":"2018","unstructured":"Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez M, Huledal G, Kolly C, L\u00fc\u00f6nd RM, Machauer R, Veenstra SJ, Hurth K (2018) The BACE-1 inhibitor CNP 520 for prevention trials in Alzheimer\u2019s disease. EMBO Mol Med 10:e9316","journal-title":"EMBO Mol Med"},{"key":"1983_CR114","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/01.jnen.0000240466.10758.ce","volume":"65","author":"JAR Nicoll","year":"2006","unstructured":"Nicoll JAR, Barton E, Boche D, Neal JW, Ferrer I, Thompson P, Vlachouli C, Wilkinson D, Bayer A, Games D (2006) A\u03b2 species removal after A\u03b242 immunization. J Neuropathol Exp Neurol 65:1040\u20131048","journal-title":"J Neuropathol Exp Neurol"},{"key":"1983_CR115","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semcdb.2020.03.002","volume":"105","author":"P Nie","year":"2020","unstructured":"Nie P, Vartak A, Li Y-M (2020) \u03b3-Secretase inhibitors and modulators: mechanistic insights into the function and regulation of \u03b3-secretase. Semin Cell Dev Biol 105:43\u201353. https:\/\/doi.org\/10.1016\/j.semcdb.2020.03.002","journal-title":"Semin Cell Dev Biol"},{"key":"1983_CR116","doi-asserted-by":"publisher","first-page":"16419","DOI":"10.1074\/jbc.M600617200","volume":"281","author":"DF Obregon","year":"2006","unstructured":"Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D et al (2006) ADAM10 activation is required for Green Tea (-)-Epigallocatechin-3-Gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 281:16419\u201316427. https:\/\/doi.org\/10.1074\/jbc.M600617200","journal-title":"J Biol Chem"},{"key":"1983_CR117","doi-asserted-by":"publisher","first-page":"S374","DOI":"10.1016\/j.jalz.2013.08.283","volume":"10","author":"B Olsson","year":"2014","unstructured":"Olsson B, Legros L, Guilhot F, Str\u00f6mberg K, Smith J, Livesey FJ, Wilson DH, Zetterberg H, Blennow K (2014) Imatinib treatment and A\u03b242 in humans. Alzheimers Dement 10:S374\u2013S380. https:\/\/doi.org\/10.1016\/j.jalz.2013.08.283","journal-title":"Alzheimers Dement"},{"key":"1983_CR118","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, Cassetta E, Woodward M, Boada M, van Dyck CH et al (2022) Evaluating the safety and efficacy of Crenezumab vs placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol 79:1113\u20131121. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2909","journal-title":"JAMA Neurol"},{"key":"1983_CR119","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2174\/138920311795860188","volume":"12","author":"D Papy-Garcia","year":"2011","unstructured":"Papy-Garcia D, Christophe M, Huynh MB, Fernando S, Ludmilla S, Sepulveda-Diaz JE, Raisman-Vozari R (2011) Glycosaminoglycans, Protein Aggregation and Neurodegeneration. Curr Protein Pept Sci 12:258\u2013268. https:\/\/doi.org\/10.2174\/138920311795860188","journal-title":"Curr Protein Pept Sci"},{"key":"1983_CR120","unstructured":"Pharmaceuticals, N. A Study of CAD106 and CNP520 versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer\u2019s Disease (Generation S1). 2019."},{"key":"1983_CR121","doi-asserted-by":"crossref","first-page":"28737","DOI":"10.1074\/jbc.M115.675215","volume":"290","author":"E Prade","year":"2015","unstructured":"Prade E, Bittner HJ, Sarkar R, Del Amo JML, Althoff-Ospelt G, Multhaup G, Hildebrand PW, Reif B (2015) Structural mechanism of the interaction of Alzheimer disease A\u03b2 fibrils with the non-steroidal anti-inflammatory drug (NSAID) sulindac sulfide. J Biol Chem 290:28737\u201328745","journal-title":"J Biol Chem"},{"key":"1983_CR122","doi-asserted-by":"crossref","unstructured":"Prade, E.; Barucker, C.; Sarkar, R.; Althoff-Ospelt, G.; Lopez del Amo, J.M.; Hossain, S.; Zhong, Y.; Multhaup, G.; Reif, B. Sulindac Sulfide Induces the Formation of Large Oligomeric Aggregates of the Alzheimer\u2019s Disease Amyloid-\u03b2 Peptide Which Exhibit Reduced Neurotoxicity. Biochemistry 2016, 55, 1839\u20131849.","DOI":"10.1021\/acs.biochem.5b01272"},{"key":"1983_CR123","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000113700","volume":"5","author":"M Pride","year":"2008","unstructured":"Pride M, Seubert P, Grundman M, Hagen M, Eldridge J, Black RS (2008) Progress in the active immunotherapeutic approach to Alzheimer\u2019s disease: clinical investigations into AN1792-associated meningoencephalitis. Neurodegener Dis 5:194\u2013196","journal-title":"Neurodegener Dis"},{"key":"1983_CR124","doi-asserted-by":"publisher","unstructured":"Puzzo, D.; Privitera, L.; Fa\u2019, M.; Staniszewski, A.; Hashimoto, G.; Aziz, F.; Sakurai, M.; Ribe, E.M.; Troy, C.M.; Mercken, M.; et al. Endogenous Amyloid-\u03b2 Is Necessary for Hippocampal Synaptic Plasticity and Memory. Ann. Neurol. 2011, 69, 819\u2013830, https:\/\/doi.org\/10.1002\/ana.22313.","DOI":"10.1002\/ana.22313"},{"key":"1983_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2015.00136","volume":"7","author":"A Ramanathan","year":"2015","unstructured":"Ramanathan A, Nelson AR, Sagare AP, Zlokovic BV (2015) Impaired vascular-mediated clearance of brain amyloid beta in Alzheimer\u2019s disease: the role, regulation and restoration of LRP1. Front Aging Neurosci 7:136. https:\/\/doi.org\/10.3389\/fnagi.2015.00136","journal-title":"Front Aging Neurosci"},{"key":"1983_CR126","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3233\/JAD-170512","volume":"61","author":"PH Reddy","year":"2018","unstructured":"Reddy PH, Manczak M, Yin X, Grady MC, Mitchell A, Tonk S, Kuruva CS, Bhatti JS, Kandimalla R, Vijayan M et al (2018) Protective Effects of Indian Spice Curcumin Against Amyloid-\u03b2 in Alzheimer\u2019s Disease. J Alzheimers Dis 61:843\u2013866. https:\/\/doi.org\/10.3233\/JAD-170512","journal-title":"J Alzheimers Dis"},{"key":"1983_CR127","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1689-23.2024","author":"Q Ren","year":"2024","unstructured":"Ren Q, Wang S, Li J, Cao K, Zhuang M, Wu M, Geng J, Jia Z, Xie W, Liu A (2024) Novel social stimulation ameliorates memory deficit in Alzheimer\u2019s disease model through activating \u03b1-secretase. J Neurosci. https:\/\/doi.org\/10.1523\/JNEUROSCI.1689-23.2024","journal-title":"J Neurosci"},{"key":"1983_CR128","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.brainres.2008.02.107","volume":"1214","author":"K Rezai-Zadeh","year":"2008","unstructured":"Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J (2008) Green Tea Epigallocatechin-3-Gallate (EGCG) Reduces Beta-Amyloid Mediated Cognitive Impairment and Modulates Tau Pathology in Alzheimer Transgenic Mice. Brain Res 1214:177\u2013187. https:\/\/doi.org\/10.1016\/j.brainres.2008.02.107","journal-title":"Brain Res"},{"key":"1983_CR129","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt146","volume":"4","author":"JM Ringman","year":"2012","unstructured":"Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG et al (2012) Oral curcumin for Alzheimer\u2019s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 4:43. https:\/\/doi.org\/10.1186\/alzrt146","journal-title":"Alzheimers Res Ther"},{"key":"1983_CR130","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/alz.13532","volume":"20","author":"M Riviere","year":"2024","unstructured":"Riviere M, Langbaum JB, Turner RS, Rinne JO, Sui Y, Cazorla P, Ricart J, Meneses K, Caputo A, Tariot PN (2024) Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE \u03954 homozygotes. Alzheimers Dement 20:1839\u20131850","journal-title":"Alzheimers Dement"},{"key":"1983_CR131","doi-asserted-by":"crossref","first-page":"714","DOI":"10.2174\/1567205011666140618104430","volume":"11","author":"N Ronsisvalle","year":"2014","unstructured":"Ronsisvalle N, Di Benedetto G, Parenti C, Amoroso S, Bernardini R, Cantarella G (2014) CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25\u201335 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro. Curr Alzheimer Res 11:714\u2013724","journal-title":"Curr Alzheimer Res"},{"key":"1983_CR132","doi-asserted-by":"publisher","unstructured":"Rosales Jubal, E.; Schwalm, M.; Dos Santos Guilherme, M.; Schuck, F.; Reinhardt, S.; Tose, A.; Barger, Z.; Roesler, M.K.; Ruffini, N.; Wierczeiko, A.; et al. Acitretin Reverses Early Functional Network Degradation in a Mouse Model of Familial Alzheimer\u2019s Disease. Sci. Rep. 2021, 11, 6649, https:\/\/doi.org\/10.1038\/s41598-021-85912-0.","DOI":"10.1038\/s41598-021-85912-0"},{"key":"1983_CR133","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1001\/jamaneurol.2019.4182","volume":"77","author":"RN Rosenberg","year":"2020","unstructured":"Rosenberg RN, Lambracht-Washington D (2020) Active immunotherapy to prevent Alzheimer disease\u2014a DNA amyloid \u03b2 1\u201342 trimer vaccine. JAMA Neurol 77:289\u2013290","journal-title":"JAMA Neurol"},{"key":"1983_CR134","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.neurobiolaging.2013.10.085","volume":"35","author":"WI Rosenblum","year":"2014","unstructured":"Rosenblum WI (2014) Why Alzheimer trials fail: removing soluble oligomeric beta amyloid is essential, inconsistent, and difficult. Neurobiol Aging 35:969\u2013974. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2013.10.085","journal-title":"Neurobiol Aging"},{"key":"1983_CR135","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202560","author":"KD Rynearson","year":"2021","unstructured":"Rynearson KD, Ponnusamy M, Prikhodko O, Xie Y, Zhang C, Nguyen P, Hug B, Sawa M, Becker A, Spencer B et al (2021) Preclinical validation of a potent \u03b3-secretase modulator for Alzheimer\u2019s disease prevention. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20202560","journal-title":"J Exp Med"},{"key":"1983_CR136","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","volume":"77","author":"S Salloway","year":"2011","unstructured":"Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C et al (2011) A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 77:1253\u20131262. https:\/\/doi.org\/10.1212\/WNL.0b013e3182309fa5","journal-title":"Neurology"},{"key":"1983_CR137","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370:322\u2013333. https:\/\/doi.org\/10.1056\/NEJMoa1304839","journal-title":"N Engl J Med"},{"key":"1983_CR138","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1021\/acsptsci.4c00400","volume":"7","author":"SK Saxena","year":"2024","unstructured":"Saxena SK, Ansari S, Maurya VK, Kumar S, Sharma D, Malhotra HS, Tiwari S, Srivastava C, Paweska JT, Abdel-Moneim AS et al (2024) Neprilysin-mediated amyloid beta clearance and its therapeutic implications in neurodegenerative disorders. ACS Pharmacol Transl Sci 7:3645\u20133657. https:\/\/doi.org\/10.1021\/acsptsci.4c00400","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1983_CR139","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s12603-009-0070-5","volume":"13","author":"A Schneeberger","year":"2009","unstructured":"Schneeberger A, Mandler M, Otava O, Zauner W, Mattner F, Schmidt W (2009) Development of AFFITOPE vaccines for Alzheimer\u2019s disease (AD)\u2014from concept to clinical testing. JNHA-the J Nutr Heal Aging 13:264\u2013267","journal-title":"JNHA-the J Nutr Heal Aging"},{"key":"1983_CR140","doi-asserted-by":"publisher","first-page":"3510","DOI":"10.1073\/pnas.1112209109","volume":"109","author":"N Sehgal","year":"2012","unstructured":"Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V (2012) Withania somnifera reverses Alzheimer\u2019s disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A 109:3510\u20133515. https:\/\/doi.org\/10.1073\/pnas.1112209109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1983_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00071","volume":"6","author":"M Shinohara","year":"2014","unstructured":"Shinohara M, Sato N, Shimamura M, Kurinami H, Hamasaki T, Chatterjee A, Rakugi H, Morishita R (2014) Possible modification of Alzheimer\u2019s disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci 6:71. https:\/\/doi.org\/10.3389\/fnagi.2014.00071","journal-title":"Front Aging Neurosci"},{"key":"1983_CR142","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1007\/s11064-023-03924-w","volume":"48","author":"N Siddiqui","year":"2023","unstructured":"Siddiqui N, Ali J, Parvez S, Najmi AK, Akhtar M (2023) Neuroprotective role of DPP-4 inhibitor Linagliptin against neurodegeneration, neuronal insulin resistance and neuroinflammation induced by intracerebroventricular streptozotocin in rat model of Alzheimer\u2019s disease. Neurochem Res 48:2714\u20132730","journal-title":"Neurochem Res"},{"key":"1983_CR143","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.neuropharm.2012.11.009","volume":"67","author":"E Siopi","year":"2013","unstructured":"Siopi E, Llufriu-Dab\u00e9n G, Cho AH, Vidal-Lletj\u00f3s S, Plotkine M, Marchand-Leroux C, Jafarian-Tehrani M (2013) Etazolate, an \u03b1-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice. Neuropharmacology 67:183\u2013192. https:\/\/doi.org\/10.1016\/j.neuropharm.2012.11.009","journal-title":"Neuropharmacology"},{"key":"1983_CR144","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13195-024-01504-w","volume":"16","author":"S Sirisi","year":"2024","unstructured":"Sirisi S, S\u00e1nchez-Aced \u00c9, Belbin O, Lle\u00f3 A (2024) APP Dyshomeostasis in the Pathogenesis of Alzheimer\u2019s Disease: Implications for Current Drug Targets. Alzheimers Res Ther 16:144. https:\/\/doi.org\/10.1186\/s13195-024-01504-w","journal-title":"Alzheimers Res Ther"},{"key":"1983_CR145","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2202-14-44","volume":"14","author":"S Sivilia","year":"2013","unstructured":"Sivilia S, Lorenzini L, Giuliani A, Gusciglio M, Fernandez M, Baldassarro VA, Mangano C, Ferraro L, Pietrini V, Baroc MF (2013) Multi-target action of the novel anti-Alzheimer compound CHF5074. In vivo study of long term treatment in Tg2576 mice. BMC Neurosci 14:44","journal-title":"BMC Neurosci"},{"key":"1983_CR146","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40035-022-00292-3","volume":"11","author":"C Song","year":"2022","unstructured":"Song C, Shi J, Zhang P, Zhang Y, Xu J, Zhao L, Zhang R, Wang H, Chen H (2022) Immunotherapy for Alzheimer\u2019s disease: targeting \u03b2-amyloid and beyond. Transl Neurodegener 11:18","journal-title":"Transl Neurodegener"},{"key":"1983_CR147","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R et al (2023) Trial of solanezumab in preclinical Alzheimer\u2019s disease. N Engl J Med 389:1096\u20131107. https:\/\/doi.org\/10.1056\/NEJMoa2305032","journal-title":"N Engl J Med"},{"key":"1983_CR148","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.neurobiolaging.2009.04.016","volume":"32","author":"V Srikanth","year":"2011","unstructured":"Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, M\u00fcnch G (2011) Advanced glycation endproducts and their receptor RAGE in Alzheimer\u2019s disease. Neurobiol Aging 32:763\u2013777. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2009.04.016","journal-title":"Neurobiol Aging"},{"key":"1983_CR149","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.pharmthera.2010.03.001","volume":"127","author":"M-K Sun","year":"2010","unstructured":"Sun M-K, Alkon DL (2010) Pharmacology of protein kinase C activators: cognition-enhancing and antidementic therapeutics. Pharmacol Ther 127:66\u201377. https:\/\/doi.org\/10.1016\/j.pharmthera.2010.03.001","journal-title":"Pharmacol Ther"},{"key":"1983_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031757","author":"Y Sun","year":"2024","unstructured":"Sun Y, Islam S, Michikawa M, Zou K (2024) Presenilin: a multi-functional molecule in the pathogenesis of Alzheimer\u2019s disease and other neurodegenerative diseases. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25031757","journal-title":"Int J Mol Sci"},{"key":"1983_CR151","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0002-9440(10)63269-5","volume":"165","author":"S Sung","year":"2004","unstructured":"Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VM-Y, Pratic\u00f2 D (2004) Modulation of Nuclear Factor-\u039aB activity by indomethacin influences A\u03b2 levels but not A\u03b2 precursor protein metabolism in a model of Alzheimer\u2019s disease. Am J Pathol 165:2197\u20132206","journal-title":"Am J Pathol"},{"key":"1983_CR152","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2174\/0115680266259174231006070637","volume":"24","author":"F Tadros Hakem","year":"2024","unstructured":"Tadros Hakem F, Farid Fouad Y, Arafa RK (2024) Gamma secretase as an important drug target for management of Alzheimer\u2019s disease: a comprehensive review. Curr Top Med Chem 24:109\u2013127","journal-title":"Curr Top Med Chem"},{"key":"1983_CR153","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13430","volume":"23","author":"HA Taylor","year":"2022","unstructured":"Taylor HA, Przemylska L, Clavane EM, Meakin PJ (2022) BACE1: more than just a \u03b2-secretase. Obes Rev 23:e13430. https:\/\/doi.org\/10.1111\/obr.13430","journal-title":"Obes Rev"},{"key":"1983_CR154","doi-asserted-by":"publisher","first-page":"1187411","DOI":"10.3389\/fphar.2023.1187411","volume":"14","author":"Z Tian","year":"2023","unstructured":"Tian Z, Lu X-T, Jiang X, Tian J (2023a) Bryostatin-1: a promising compound for neurological disorders. Front Pharmacol 14:1187411. https:\/\/doi.org\/10.3389\/fphar.2023.1187411","journal-title":"Front Pharmacol"},{"key":"1983_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101999","volume":"90","author":"Y Tian","year":"2023","unstructured":"Tian Y, Jing G, Zhang M (2023b) Insulin-degrading enzyme: roles and pathways in ameliorating cognitive impairment associated with Alzheimer\u2019s disease and diabetes. Ageing Res Rev 90:101999. https:\/\/doi.org\/10.1016\/j.arr.2023.101999","journal-title":"Ageing Res Rev"},{"key":"1983_CR156","unstructured":"Umibecestat."},{"key":"1983_CR157","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1177\/0269881108097630","volume":"24","author":"D Van Dam","year":"2010","unstructured":"Van Dam D, Coen K, De Deyn PP (2010) Ibuprofen modifies cognitive disease progression in an Alzheimer\u2019s mouse model. J Psychopharmacol 24:383\u2013388","journal-title":"J Psychopharmacol"},{"key":"1983_CR158","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trci.2016.12.003","volume":"3","author":"R Vandenberghe","year":"2017","unstructured":"Vandenberghe R, Riviere M-E, Caputo A, Sovago J, Maguire RP, Farlow M, Marotta G, Sanchez-Valle R, Scheltens P, Ryan JM (2017) Active A\u03b2 immunotherapy CAD106 in Alzheimer\u2019s disease: a phase 2b study. Alzheimers Dement Transl Res Clin Interv 3:10\u201322","journal-title":"Alzheimers Dement Transl Res Clin Interv"},{"key":"1983_CR159","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51705","volume":"16","author":"B Vejandla","year":"2024","unstructured":"Vejandla B, Savani S, Appalaneni R, Veeravalli RS, Gude SS (2024) Alzheimer\u2019s disease: the past, present, and future of a globally progressive disease. Cureus 16:e51705. https:\/\/doi.org\/10.7759\/cureus.51705","journal-title":"Cureus"},{"key":"1983_CR160","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2174\/156720511795256053","volume":"8","author":"B Vellas","year":"2011","unstructured":"Vellas B, Sol O, Snyder PJ, Ousset P-J, Haddad R, Maurin M, Lemari\u00e9 J-C, D\u00e9sir\u00e9 L, Pando MP (2011) EHT0202 in Alzheimer\u2019s disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 8:203\u2013212. https:\/\/doi.org\/10.2174\/156720511795256053","journal-title":"Curr Alzheimer Res"},{"key":"1983_CR161","doi-asserted-by":"publisher","first-page":"11328","DOI":"10.1523\/JNEUROSCI.0607-11.2011","volume":"31","author":"DK Verges","year":"2011","unstructured":"Verges DK, Restivo JL, Goebel WD, Holtzman DM, Cirrito JR (2011) Opposing synaptic regulation of amyloid-\u03b2 metabolism by NMDA receptors in vivo. J Neurosci 31:11328\u201311337. https:\/\/doi.org\/10.1523\/JNEUROSCI.0607-11.2011","journal-title":"J Neurosci"},{"key":"1983_CR162","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/jphp.12919","volume":"70","author":"S Verma","year":"2018","unstructured":"Verma S, Kumar A, Tripathi T, Kumar A (2018) Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer\u2019s disease therapy. J Pharm Pharmacol 70:985\u2013993. https:\/\/doi.org\/10.1111\/jphp.12919","journal-title":"J Pharm Pharmacol"},{"key":"1983_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.101988","volume":"89","author":"B Vincent","year":"2023","unstructured":"Vincent B, Maitra S (2023) BACE1-dependent metabolism of Neuregulin 1: bridging the gap in explaining the occurrence of schizophrenia-like symptoms in Alzheimer\u2019s disease with psychosis? Ageing Res Rev 89:101988. https:\/\/doi.org\/10.1016\/j.arr.2023.101988","journal-title":"Ageing Res Rev"},{"key":"1983_CR164","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/FBP.0b013e3282feb0d2","volume":"19","author":"D Wang","year":"2008","unstructured":"Wang D, Darwish DS, Schreurs BG, Alkon DL (2008) Analysis of long-term cognitive-enhancing effects of Bryostatin-1 on the rabbit (Oryctolagus cuniculus) nictitating membrane response. Behav Pharmacol 19:245\u2013256. https:\/\/doi.org\/10.1097\/FBP.0b013e3282feb0d2","journal-title":"Behav Pharmacol"},{"key":"1983_CR165","first-page":"2389","volume":"20","author":"Y-Q Wang","year":"2016","unstructured":"Wang Y-Q, Qu D-H, Wang K (2016) Therapeutic approaches to Alzheimer\u2019s disease through stimulating of non-amyloidogenic processing of amyloid precursor protein. Eur Rev Med Pharmacol Sci 20:2389\u20132403","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1983_CR166","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JAD-220240","volume":"90","author":"S Wei","year":"2022","unstructured":"Wei S, Dang L, Gao F, Wang J, Wang J, Qu Q (2022) Effects of simvastatin on plasma amyloid-\u03b2 transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial. J Alzheimers Dis 90:349\u2013362","journal-title":"J Alzheimers Dis"},{"key":"1983_CR167","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1750-3639.2005.tb00102.x","volume":"15","author":"T Wisniewski","year":"2005","unstructured":"Wisniewski T, Frangione B (2005) Immunological and Anti-chaperone Therapeutic Approaches for Alzheimer Disease. Brain Pathol 15:72\u201377","journal-title":"Brain Pathol"},{"key":"1983_CR168","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bcp.2013.12.020","volume":"88","author":"T Wisniewski","year":"2014","unstructured":"Wisniewski T, Goni F (2014) Immunotherapy for Alzheimer\u2019s disease. Biochem Pharmacol 88:499\u2013507","journal-title":"Biochem Pharmacol"},{"key":"1983_CR169","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17460441.2023.2277350","volume":"19","author":"MS Wolfe","year":"2024","unstructured":"Wolfe MS (2024) \u03b3-Secretase: Once and Future Drug Target for Alzheimer\u2019s Disease. Expert Opin Drug Discov 19:5\u20138","journal-title":"Expert Opin Drug Discov"},{"key":"1983_CR170","doi-asserted-by":"crossref","first-page":"12876","DOI":"10.1074\/jbc.M311652200","volume":"279","author":"GT Wong","year":"2004","unstructured":"Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee H-JJ (2004) Chronic treatment with the \u03b3-secretase inhibitor LY-411,575 inhibits \u03b2-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279:12876\u201312882","journal-title":"J Biol Chem"},{"key":"1983_CR171","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182266","author":"Y Xu","year":"2020","unstructured":"Xu Y, Wang C, Wey H-Y, Liang Y, Chen Z, Choi SH, Ran C, Rynearson KD, Bernales DR, Koegel RE et al (2020) Molecular imaging of Alzheimer\u2019s disease-related gamma-secretase in mice and nonhuman primates. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20182266","journal-title":"J Exp Med"},{"key":"1983_CR172","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JAD-220673","volume":"90","author":"C Xu","year":"2022","unstructured":"Xu C, Zhao L, Dong C (2022) A review of application of A\u03b242\/40 ratio in diagnosis and prognosis of Alzheimer\u2019s disease. J Alzheimers Dis 90:495\u2013512. https:\/\/doi.org\/10.3233\/JAD-220673","journal-title":"J Alzheimers Dis"},{"key":"1983_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115374","volume":"28","author":"Z Yang","year":"2020","unstructured":"Yang Z, Song Q, Cao Z, Yu G, Liu Z, Tan Z, Deng Y (2020) Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer\u2019s disease. Bioorg Med Chem 28:115374. https:\/\/doi.org\/10.1016\/j.bmc.2020.115374","journal-title":"Bioorg Med Chem"},{"key":"1983_CR174","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2021\/e2348","volume":"76","author":"L Yang","year":"2021","unstructured":"Yang L, Liu Y, Wang Y, Li J, Liu N (2021) Azeliragon ameliorates Alzheimer\u2019s disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway. Clinics 76:e2348. https:\/\/doi.org\/10.6061\/clinics\/2021\/e2348","journal-title":"Clinics"},{"key":"1983_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043841","author":"Z Yang","year":"2023","unstructured":"Yang Z, Zou Y, Wang L (2023) Neurotransmitters in prevention and treatment of Alzheimer\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24043841","journal-title":"Int J Mol Sci"},{"key":"1983_CR176","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12967-024-05248-x","volume":"22","author":"LX Yi","year":"2024","unstructured":"Yi LX, Tan EK, Zhou ZD (2024) Passive immunotherapy for Alzheimer\u2019s disease: challenges & future directions. J Transl Med 22:430","journal-title":"J Transl Med"},{"key":"1983_CR177","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcph.249","volume":"54","author":"Y Yu","year":"2014","unstructured":"Yu Y, Logovinsky V, Schuck E, Kaplow J, Chang M-K, Miyagawa T, Wong N, Ferry J (2014) Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel \u03b3-secretase modulator, E2212, in healthy human subjects. J Clin Pharmacol 54:528\u2013536. https:\/\/doi.org\/10.1002\/jcph.249","journal-title":"J Clin Pharmacol"},{"key":"1983_CR178","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/jnc.15260","volume":"156","author":"CM Yuede","year":"2021","unstructured":"Yuede CM, Wallace CE, Davis TA, Gardiner WD, Hettinger JC, Edwards HM, Hendrix RD, Doherty BM, Yuede KM, Burstein ES et al (2021) Pimavanserin, a 5HT(2A) receptor inverse agonist, rapidly suppresses A\u03b2 production and related pathology in a mouse model of Alzheimer\u2019s disease. J Neurochem 156:658\u2013673. https:\/\/doi.org\/10.1111\/jnc.15260","journal-title":"J Neurochem"},{"key":"1983_CR179","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/jnc.15096","volume":"158","author":"F Zeng","year":"2021","unstructured":"Zeng F, Liu Y, Huang W, Qing H, Kadowaki T, Kashiwazaki H, Ni J, Wu Z (2021) Receptor for advanced glycation end products up-regulation in cerebral endothelial cells mediates cerebrovascular-related amyloid \u03b2 accumulation after Porphyromonas gingivalis infection. J Neurochem 158:724\u2013736","journal-title":"J Neurochem"},{"key":"1983_CR180","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1515\/revneuro-2017-0013","volume":"28","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Chen X, Zhao Y, Ponnusamy M, Liu Y (2017) The role of Ubiquitin Proteasomal System and Autophagy-Lysosome Pathway in Alzheimer\u2019s disease. Rev Neurosci 28:861\u2013868. https:\/\/doi.org\/10.1515\/revneuro-2017-0013","journal-title":"Rev Neurosci"},{"key":"1983_CR181","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3389\/fnmol.2020.00137","volume":"13","author":"J Zhao","year":"2020","unstructured":"Zhao J, Liu X, Xia W, Zhang Y, Wang C (2020) Targeting amyloidogenic processing of APP in Alzheimer\u2019s disease. Front Mol Neurosci 13:137","journal-title":"Front Mol Neurosci"},{"key":"1983_CR182","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/JAD-160411","volume":"55","author":"F Zimetti","year":"2017","unstructured":"Zimetti F, Caffarra P, Ronda N, Favari E, Adorni MP, Zanotti I, Bernini F, Barocco F, Spallazzi M, Galimberti D et al (2017) Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer\u2019s disease. J Alzheimers Dis 55:315\u2013320. https:\/\/doi.org\/10.3233\/JAD-160411","journal-title":"J Alzheimers Dis"},{"key":"1983_CR183","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1111\/febs.16939","volume":"291","author":"J \u017bukowska","year":"2024","unstructured":"\u017bukowska J, Moss SJ, Subramanian V, Acharya KR (2024) Molecular basis of selective amyloid-\u03b2 degrading enzymes in Alzheimer\u2019s disease. FEBS J 291:2999\u20133029. https:\/\/doi.org\/10.1111\/febs.16939","journal-title":"FEBS J"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01983-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-01983-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-01983-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:05:04Z","timestamp":1761332704000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-01983-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":183,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1983"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-01983-9","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"29 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}